An 80-year-old woman who had undergone aortic valve replacement for aortic valve stenosis was hospitalized for congestive heart failure and paroxysmal atrial fibrillation 4 years prior to the current presentation. At that time, she started receiving oral amiodarone, and she took amiodarone for 4 years. She visited our hospital because dementia had progressed over the previous 2 months, leaving her incapacitated and unable to care for herself. She presented with a blood pressure of 120/48 mmHg, a regular pulse of 52 beats per minute, and a body temperature of 35.6°C. Blood tests revealed liver dysfunction and hypothyroidism. Her laboratory findings were as follows: aspartate aminotransferase, 86 IU/L; alanine aminotransferase, 76 IU/L; total bilirubin, 1.82 mg/dL; thyroid-stimulating hormone, 91.29 μU/mL (reference range, 0.24 to 3.72); free thyroxine level, 0.31 ng/dL (reference range, 0.94 to 1.52); free triiodothyronine level, 0.92 pg/mL (reference range, 2.01 to 3.72); thyroglobulin antibody, < 40 U/mL; and thyroid peroxidase antibody, < 50 U/mL.
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Abdominal plain computed tomography (CT) revealed an increased liver density (Fig. 1) . These disorders were determined to be attributable to an overdose of amiodarone, and the drug was discontinued. Thyroid hormone replacement relieved her dementia; the dosage of thyroid hormone preparations was decreased over time and eventually discontinued. Moreover, the liver dysfunction gradually resolved. An abdominal plain CT scan performed 1 year later revealed a decrease in the high liver density (Fig. 2) . During this period, no recurrence of paroxysmal atrial fibrillation was detected.
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